Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Pohl

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
BMC Neurology|May 22, 2009
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeJessica M Nielsen, Christoph Pohl, Chris H Polman, et al.
Journal of Neurology|March 19, 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND studyChristian Lampl, Stefan Nagl, Barry Arnason, et al.
Journal of Neurology|May 15, 2016
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trialSven Schippling, Paul O'Connor, Volker Knappertz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
The Journal of Rheumatology|August 18, 2009
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group)Clifton O Bingham, Christoph Pohl, Thasia G Woodworth, et al.
Archives of Neurology|November 11, 2009
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT studyBastiaan Moraal, Christoph Pohl, Bernard M J Uitdehaag, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
BMC Neurology|May 22, 2009
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeJessica M Nielsen, Christoph Pohl, Chris H Polman, et al.
Journal of Neurology|March 19, 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND studyChristian Lampl, Stefan Nagl, Barry Arnason, et al.
Journal of Neurology|May 15, 2016
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trialSven Schippling, Paul O'Connor, Volker Knappertz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
The Journal of Rheumatology|August 18, 2009
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group)Clifton O Bingham, Christoph Pohl, Thasia G Woodworth, et al.
Archives of Neurology|November 11, 2009
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT studyBastiaan Moraal, Christoph Pohl, Bernard M J Uitdehaag, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Pageof 7